Oral delivery of non-viral nucleic acid-based therapeutics - do we have the guts for this?

O'Driscoll, Caitriona M;Bernkop-Schnürch, Andreas;Friedl, Julian D;Préat, Véronique;Jannin, Vincent
(2019) European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences — Vol. 133, n° 133, p. 190-204 (2019)

Files

ODRISCOLL.pdf
  • Open Access
  • Adobe PDF
  • 1.22 MB
Download

Details

Authors
  • O'Driscoll, Caitriona M
    Author
  • Bernkop-Schnürch, Andreas
    Author
  • Friedl, Julian D
    Author
  • Préat, VéroniqueUCLouvain
    Author
  • Jannin, Vincent
    Author
Abstract
Gene therapy with RNA and pDNA-based drugs is limited by poor enzymatic stability and poor cellular permeation. The delivery of nucleic acids, in particular by the oral route, remains a major hurdle. This review will focus on the barriers to the oral delivery of nucleic acids and the strategies, in particular formulation strategies, which have been developed to overcome these barriers. Due to their very low oral bioavailability, the most obvious and most investigated biomedical applications for their oral delivery are related to the local treatment of inflammatory bowel diseases and colorectal cancers. Preclinical data but not yet clinical studies support the potential use of the oral route for the local delivery of formulated nucleic acid-based drugs.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

O’Driscoll, C. M., Bernkop-Schnürch, A., Friedl, J. D., Préat, V., & Jannin, V. (2019). Oral delivery of non-viral nucleic acid-based therapeutics - do we have the guts for this? European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 133(133), 190-204. https://doi.org/10.1016/j.ejps.2019.03.027 (Original work published 2019)